Trial Profile
Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Spebrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 19 May 2017 Results of a population pharmacokinetic model developed from AVL-292-004 and AVL-292-003 studies (n=145), published in the Journal of Clinical Pharmacology.
- 26 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 20 May 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.